A Phase 2 Randomized Blinded Placebo Controlled Comparison of the Safety Pharmacokinetics and Pharmacodynamics of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines in Healthy Adult Subjects

Trial Profile

A Phase 2 Randomized Blinded Placebo Controlled Comparison of the Safety Pharmacokinetics and Pharmacodynamics of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines in Healthy Adult Subjects

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs SYN 023 (Primary) ; Rabies vaccine
  • Indications Rabies
  • Focus Pharmacodynamics
  • Acronyms RabiesMab
  • Sponsors Synermore Biologics
  • Most Recent Events

    • 14 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
    • 14 Aug 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Oct 2017.
    • 10 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top